July 2022 FDA Recall Divalproex Sodium by Amneal Pharmaceuticals Of New York, Llc
D-1362-2022 - Failed dissolution specifications.
This Class II drug recall was voluntarily initiated by Amneal Pharmaceuticals Of New York, Llc on July 27, 2022 for the product Divalproex Sodium. The FDA reported the reason for recall as failed dissolution specifications.. The product was distributed Nationwide and the recall is currently terminated.
Recall Number: D-1362-2022
Failed dissolution specifications.
07-27-2022
08-31-2022
4,309 bottles
Recall Profile & Regulatory Data
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
The firm responsible for the recall.
Amneal Pharmaceuticals of New York, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
General area of initial distribution.
USA nationwide
08-17-2023
Product Description About Product Description
Full technical description of the product.
Full technical description of the product.
Divalproex Sodium Extended Release Tablets, USP, 250 mg, packaged in 100-count bottle, Rx only, Manufactured by: Amneal Pharmaceuticals, India, Distributed by: Amneal Pharmaceuticals, Bridgewater, NJ, NDC 65162-755-10
Batch or Lot Expiration Information
Lot# : AR210705, Exp 04/2024
